M&As this week: Oncolys BioPharma, Alira Health, NL-HOLDING

Oncolys BioPharma has agreed to purchase an additional 8.4% stake in Precision Virologics from US-based oncolytic virus immunotherapy products developer Unleash Immuno Oncolytics.

As part of the acquisition, Oncolys BioPharma will purchase 294,118 shares of Precision Virologics from Unleash for $0.33m. Oncolys BioPharma’s stake will then increase from the existing 14.6% to 23%.

“Alira Health has announced the acquisition of Clinical Assistance Programs (CAP).”

Oncolys BioPharma is a biopharmaceutical company based in Japan, while Precision Virologics is a biotechnology company based in the US.

Unleash Immuno Oncolytics has simultaneously announced plans to raise $3m through the private placement of convertible bonds.

Alira Health has announced the acquisition of Clinical Assistance Programs (CAP).

Based in the US, Alira Health is an international healthcare and life science advisory firm, while CAP is involved in providing clinical trial management and consulting services.

NL-HOLDING has acquired ProCrea Group, Archimed and Instituto de Medicina Reproductiva (IMER).

The German healthcare services provider has acquired all three companies in partnership with Oaktree Capital Management.

ProCrea and Instituto de Medicina Reproductiva are assisted-reproduction service providers based in Switzerland and Spain respectively, while Archimedis is an Italian company involved in the provision of specialised diagnostic services.

Free Whitepaper

Revolutionising chromatography and clarification in biopharma production

Biopharma companies are under constant pressure to improve productivity, maintain product purity, and cut costs. Yet this is far from straightforward. Process intensification is desired, but there are barriers to making processes more efficient. Chromatography and clarification play vital parts in biopharma manufacturing, yet there is room for improvement in processes to eliminate inefficiencies and increase yield. Single-stage clarification technologies, such as 3M™ Harvest RC Chromatographic Clarifier, could play a vital role in this journey, by simplifying what would otherwise be a time-consuming and complex clarification train. This document delves into the history of chromatography and clarification, addresses problems, proposes solutions, and offers a glimpse into what the future may look like after a revolution in biopharma production processing. Download to learn more.

By 3M

The information you provide are used by 3M Company and its group companies, in accordance with 3M Global Privacy Policy as shown at 3M.com/privacy, for the purpose of (i) following up with you via email or telephone on any event sponsored / co-organized / participated by 3M, your questions, interests or requests; (ii) making materials available to you; and (iii) inviting you to future events; and (iv) based on your consent, sending you newsletters, advertisements, surveys and information about promotions and offers of 3M Company and its group companies via email. Please use the Intake form to object. EMEA residents: please read 3M privacy notice, opt in language & exact information on 3M data controller relevant to your location here

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.